Dossier assessment

Sarilumab (polymyalgia rheumatica) – Benefit assessment according to §35a Social Code Book V

Report documents

Indication:

Adults with polymyalgia rheumatica who have had an inadequate response to corticosteroids or who experience a relapse during corticosteroid taper

Result of dossier assessment:

Patients for whom corticosteroids are the appropriate treatment of physician’s choice: added benefit not proven
Patients for whom the combination of corticosteroids with methotrexate is the appropriate treatment of physician’s choice: added benefit not proven

Project no.: A25-18
Commission: Commission awarded on 04.02.2025 by the Federal Joint Committee (GBA).
Report type: Dossier assessment
Status: Commission completed
Department/Division: Drug Assessment
Topic: Muscles, bones and joints
Note: After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
DOI: https://doi.org/10.60584/A25-18_en

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.